Showing 411-420 of 805 results for "".
- UK’s First TransForm Inlay Procedure Performed by Sheraz Daya, MDhttps://modernod.com/news/uks-first-transform-inlay-procedure-performed-by-sheraz-daya-md/2476668/The first patients in the UK have undergone the TransForm Corneal Allograft (TCA) procedure, which was performed by Sheraz Daya, MD, FACP, FACS, FRCS(Ed), FRCOphth. TCA is a new procedur
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S
- Geoff Tabin, MD, Co-Founder of Global NGO HCP Cureblindness, Steps Into New Rolehttps://modernod.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/Effective immediately, Geoff Tabin, MD, will step down as Board Chair of the global nonprofit HCP Cureblindness (Himalayan Cataract Project), but will maintain an active role on the Board as Medical Director. Long-time HCP volunteer and Board Member, Matt Oliva, MD, will lead HCP into its excitin
- Azura Ophthalmics Enrolls First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with MGDhttps://modernod.com/news/azura-ophthalmics-enrolls-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-mgd/2482307/Azura Ophthalmics announced that the first patient has been enrolled in the ASTRO study—a phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of meibomian gland dysfunction (MGD). "AZR-MD-001 has already dem
- Julia Haller, MD, Named CEO of Wills Eye Hospitalhttps://modernod.com/news/julia-haller-md-named-ceo-of-wills-eye-hospital/2482897/Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital, will also become the hospital's next Chief Executive Officer. Dr. Haller assumed the expanded leadership post on July 18, succeeding longtime CEO Joseph P. Bilson, who reti
- Topcon Healthcare Appoints Daniela Ferrara, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/topcon-healthcare-appoints-daniela-ferrara-md-phd-as-chief-medical-officer/2482764/Topcon Healthcare announced the appointment of Daniela Ferrara, MD, PhD, as its new Chief Medical Officer (CMO). In her new role, Dr. Ferrara will lead Topcon Healthcare’s global medical strategy, overseeing clinical r
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- Cathleen McCabe, MD, Appointed Strategic Medical Advisor at Bausch + Lombhttps://modernod.com/news/cathleen-mccabe-md-appointed-strategic-medical-advisor-at-bausch-lomb/2482507/Bausch + Lomb has appointed Cathleen McCabe, MD, as Strategic Medical Advisor. According to B+L, in this new consultancy role, Dr. McCabe will contribute her expertise to Bausch + Lomb’s product portfolio expansion and collaborate with the research and development team to drive in
- Richard Rosen, MD, Receives Founders Award From ASRShttps://modernod.com/news/richard-rosen-md-receives-founders-award-from-asrs/2482366/The American Society of Retina Specialists (ASRS) is honoring Richard B. Rosen, MD, ScD (hon), FACS, FASRS, FARVO, CRA, the Belinda Bingham Pierce and Gerald G. Pierce Distinguished Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai, with
- RevOpsis Names Emmett Cunningham, MD, PhD, to Strategic Advisory Boardhttps://modernod.com/news/revopsis-names-emmett-cunningham-md-phd-to-strategic-advisory-board/2482273/RevOpsis Therapeutics announced the appointment of Emmett Cunningham, MD, PhD, to its Strategic Advisory Board (SAB) and as a private investor. Dr. Cunningham brings more than 20 years of experience as a full-time entrepreneur and investor to his new role with RevOpsis. Dr. Cunning